Effects of dual antiplatelet therapy de-escalation on the prognosis of acute coronary syndrome patients at high risk of ischemia who underwent percutaneous coronary intervention

Abstract

According to the type and dosage of antiplatelet drugs, the study included 679 patients in the clopidogrel group, 469 patients in the ticagrelor group, 76 patients in de-escalation group 1, and 111 patients in de-escalation group 2. According to the laboratory test results, the N-terminal proBNP level in de-escalation group 1 (393.00 [107.00, 450.00] ng/L) was lower than that in the clopidogrel group (465.00 [153.25, 1105.00] ng/L) and the ticagrelor group (569.00 [233.75, 1337.75] ng/L) (P = 0.005, P <0.001, respectively) [Supplementary Table 3, http://links.lww.com/CM9/B891]. [...]for the standard group of patients who started using clopidogrel, the proportion of HBR-ARC high-risk patients was the highest, with statistical significance among groups. [...]for ACS patients with high ischemic risk undergoing PCI, a de-escalation treatment regimen of clopidogrel at 3 months increased the incidence of MACCE compared with an